Table 3.
CES association with chemotherapy sensitivity in the MDACC-based dataset.
| Univariate Analysis |
Multivariable Analysis |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signatures | N | pCR rate |
OR | Lower 95% |
Upper 95% |
p- value |
OR | Lower 95% |
Upper 95% |
p- value |
| Age (cont. variable) | - | - | 1.0 | 0.93 | 1.02 | 0.251 | 1.0 | 0.92 | 1.02 | 0.205 |
| Tumor size | ||||||||||
| T0-T2 | 153 | 8% | 1.0 | - | - | - | 1.0 | - | - | - |
| T3-T4 | 107 | 9% | 1.1 | 0.47 | 2.63 | 0.813 | 0.6 | 0.22 | 1.70 | 0.341 |
| Nodal status | ||||||||||
| N0 | 96 | 7% | 1.0 | - | - | - | 1.0 | - | - | - |
| N1 | 125 | 9% | 1.2 | 0.46 | 3.29 | 0.685 | 0.9 | 0.30 | 2.78 | 0.882 |
| N2-3 | 39 | 13% | 1.9 | 0.56 | 6.29 | 0.312 | 1.0 | 0.24 | 4.51 | 0.965 |
| Grade | ||||||||||
| 1 | 26 | 4% | 1.0 | - | - | - | 1.0 | - | - | - |
| 2 | 130 | 4% | 1.0 | 0.11 | 8.93 | 1.000 | 0.7 | 0.07 | 6.88 | 0.753 |
| 3 | 89 | 17% | 5.1 | 0.64 | 40.34 | 0.125 | 1.8 | 0.18 | 18.42 | 0.608 |
| PAM50 | ||||||||||
| Luminal A | 134 | 3% | 1.0 | - | - | - | 1.0 | - | - | - |
| Luminal B | 99 | 15% | 5.8 | 1.86 | 18.08 | 0.002 | 1.2 | 0.25 | 6.28 | 0.792 |
| HER2-E | 6 | 0% | 0.0 | - | - | 0.989 | 0.0 | - | - | 0.991 |
| Basal-like | 7 | 29% | 13.0 | 1.91 | 88.50 | 0.009 | 0.4 | 0.02 | 9.97 | 0.586 |
| Normal-like | 14 | 14% | 5.4 | 0.90 | 32.69 | 0.065 | 1.7 | 0.23 | 12.75 | 0.602 |
| CES | ||||||||||
| CES-E | 134 | 2% | 1.0 | - | - | - | - | - | - | - |
| CES-U | 67 | 9% | 4.3 | 1.04 | 17.75 | 0.044 | - | - | - | - |
| CES-C | 59 | 24% | 13.6 | 3.73 | 49.46 | <0.001 | - | - | - | - |
| CES (cont. variable) | - | - | 0.2 | 0.08 | 0.40 | <0.001 | 0.2 | 0.03 | 0.77 | 0.022 |